Document Detail

Treatment of porphyria cutanea tarda by the effect of chloroquine on the liver.
MedLine Citation:
PMID:  7632437     Owner:  NLM     Status:  MEDLINE    
Porphyria cutanea tarda (PCT) is characterized by cutaneous symptoms in association with hepatic accumulation and urinary excretion of mainly uro- and heptacarboxyporphyrins. 24 PCT patients excreting urinary porphyrins between 1.9 and 5.8 mumol/24 h (normal < 0.2) were treated with chloroquine at a dose of 125 mg twice a week. During the first phase of therapy urinary porphyrin excretion transiently increased 1.1- to 2.9-fold indicating a phase of mobilization. A slight initial elevation was also found regarding the activities of serum aminotransferases reflecting the hepatotoxic effect of chloroquine. The clinical symptoms disappeared after a period ranging from 2 to 6 months, and after an average of 12 months the porphyrin excretion in all patients had returned to nearly normal values.
A Freesemann; M Frank; I Sieg; M O Doss
Related Documents :
19628947 - Comparison of transobturator vaginal tape and retropubic tension-free vaginal tape: cli...
9688247 - A population based, randomized, controlled trial of conservative treatment for urinary ...
3315777 - Treatment of urgency and urge incontinence with flavoxate in the people's republic of c...
20434257 - Updated systematic review and meta-analysis of the comparative data on colposuspensions...
8919437 - Strength after surgical repair of the rotator cuff.
25420397 - Efficacy of sling procedures for treatment of female stress urinary incontinence.
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Skin pharmacology : the official journal of the Skin Pharmacology Society     Volume:  8     ISSN:  1011-0283     ISO Abbreviation:  Skin Pharmacol.     Publication Date:  1995  
Date Detail:
Created Date:  1995-09-11     Completed Date:  1995-09-11     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8810069     Medline TA:  Skin Pharmacol     Country:  SWITZERLAND    
Other Details:
Languages:  eng     Pagination:  156-61     Citation Subset:  IM    
Division of Clinical Biochemistry, Philipps University, Marburg, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Chloroquine / therapeutic use*
Chromatography, High Pressure Liquid
Chronic Disease
Liver / drug effects,  metabolism*
Liver Function Tests
Middle Aged
Porphyria Cutanea Tarda / drug therapy*,  enzymology
Porphyrins / urine
Spectrophotometry, Ultraviolet
Transaminases / metabolism
Reg. No./Substance:
0/Porphyrins; 54-05-7/Chloroquine; EC 2.6.1.-/Transaminases

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Inhibition of cytokine gene expression in mouse skin by subcutaneous injection of cyclosporine.
Next Document:  Effects of human recombinant interferon-alpha 2b on P450-dependent isozymes in rat liver and skin.